DMP.DE लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 21:05):

Stats
आज की मात्रा	15 809.00
औसत मात्रा	22 056.00
बाजार मूल्य	1.84B
EPS	€0 ( 2024-03-27 )
अगली कमाई की तारीख	( €0 ) 2024-05-15
Last Dividend	€1.050 ( 2023-06-15 )
Next Dividend	€0 ( N/A )
P/E	29.44
ATR14	€0.100 (0.29%)

मात्रा सहसंबंध

लंबा: -0.05 (neutral)

छोटा: -0.18 (neutral)

Signal:(53.844) Neutral

Dermapharm Holding SE सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Dermapharm Holding SE सहसंबंध - मुद्रा/वस्त्र

-0.57
( weak negative )

-0.49
( neutral )

0.00
( neutral )

-0.12
( neutral )

0.52
( weak )

0.55
( weak )

Dermapharm Holding SE वित्तीय

Annual	2023
राजस्व:	€1.14B
सकल लाभ:	€342.86M (30.20 %)
EPS:	€1.160

FY	2023
राजस्व:	€1.14B
सकल लाभ:	€342.86M (30.20 %)
EPS:	€1.160

FY	2022
राजस्व:	€1.02B
सकल लाभ:	€660.83M (64.49 %)
EPS:	€2.49

FY	2021
राजस्व:	€942.91M
सकल लाभ:	€620.69M (65.83 %)
EPS:	€3.89

Financial Reports:

No articles found.

Dermapharm Holding SE Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0 (N/A)	€0 (N/A)	€1.050 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Dermapharm Holding SE Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.99 - Stable (0.19%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.770	2019-06-05
Last Dividend	€1.050	2023-06-15
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	€5.67	--
Avg. Dividend % Per Year	0.00%	--
Score	2.92	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.99
Div. Directional Score	7.91	--

Next Divdend (Est)
(2025-03-31)

€0.606 Estimate 3.09 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.92

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
UBK.DE	Ex Dividend Junior	2023-06-30	Sporadic	0.00%
DAP.DE	Ex Dividend Knight	2023-10-11	Quarterly	0.00%
MTX.DE	Ex Dividend Junior	2023-05-12	Annually	0.00%
2HRA.DE	Ex Dividend Junior	2023-05-24	Sporadic	0.00%
XTP.F	Ex Dividend Junior	2023-05-12	Sporadic	0.00%
ETG.DE	Ex Dividend Knight	2023-07-04	Annually	0.00%
PCG6.F	Ex Dividend Junior	2023-07-28	Quarterly	0.00%
AEND.DE	Ex Dividend Junior	2023-08-29	Semi-Annually	0.00%
HAG.DE	Ex Dividend Junior	2023-05-15	Annually	0.00%
SDF.DE	Ex Dividend Junior	2023-05-11	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0549	1.500	8.90	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0286	1.200	9.05	10.00	[0 - 0.3]
returnOnEquityTTM	0.114	1.500	9.84	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.598	0.800	7.01	5.61	[1 - 3]
quickRatioTTM	0.760	0.800	-0.238	-0.191	[0.8 - 2.5]
cashRatioTTM	0.402	1.500	8.88	10.00	[0.2 - 2]
debtRatioTTM	0.489	-1.500	1.855	-2.78	[0 - 0.6]
interestCoverageTTM	3.07	1.000	9.98	9.98	[3 - 30]
operatingCashFlowPerShareTTM	4.01	2.00	8.66	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.24	2.00	8.38	10.00	[0 - 20]
debtEquityRatioTTM	1.979	-1.500	2.08	-3.13	[0 - 2.5]
grossProfitMarginTTM	0.543	1.000	4.28	4.28	[0.2 - 0.8]
operatingProfitMarginTTM	0.156	1.000	8.88	8.88	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.203	1.000	9.99	9.99	[0.2 - 2]
assetTurnoverTTM	0.520	0.800	9.87	7.89	[0.5 - 2]
Total Score				10.83

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	29.09	1.000	7.16	0	[1 - 100]
returnOnEquityTTM	0.114	2.50	9.90	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.24	2.00	8.92	10.00	[0 - 30]
dividendYielPercentageTTM	3.12	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.01	2.00	8.66	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.190	1.000	7.74	0	[0.1 - 0.5]
Total Score				4.99

Dermapharm Holding SE

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.